Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
17 Jan 2020 Frequency, Mutational Patterns, and Genomic Profile of Hypermutated Breast Cancer Breast cancer - Translational research - Cancer Immunology and Immunotherapy
16 Jan 2020 Redesigned ESMO websites on their way
16 Jan 2020 Immune Checkpoint Inhibitors Associated with Lower Risk of Developing Severe and Any Adverse Events Compared to Chemotherapy Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
15 Jan 2020 Crizotinib in NSCLC With a MET Exon 14 Alteration Lung and other thoracic tumours - Personalised medicine - Anticancer agents & Biologic therapy
14 Jan 2020 EMA Recommends Granting Marketing Authorisation for Azacitidine Accord Haematologic malignancies - Anticancer agents & Biologic therapy
13 Jan 2020 FDA Approves Avapritinib for GIST with a PDGFRA Exon 18 Mutation Sarcomas - Personalised medicine - Anticancer agents & Biologic therapy
10 Jan 2020 EMA Recommends Extension of Therapeutic Indications for Daratumumab Haematologic malignancies - Anticancer agents & Biologic therapy
09 Jan 2020 FDA Approves Pembrolizumab for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer Genitourinary cancers - Cancer Immunology and Immunotherapy
08 Jan 2020 Oligometastatic Disease Classification Cancer in Special Situations / Population
07 Jan 2020 FDA Approves Olaparib for Germline BRCA-mutated Metastatic Pancreatic Adenocarcinoma Gastrointestinal cancers - Personalised medicine - Anticancer agents & Biologic therapy
03 Jan 2020 FDA Approves Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer Genitourinary cancers - Anticancer agents & Biologic therapy
02 Jan 2020 FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv for Metastatic Urothelial Cancer Genitourinary cancers - Anticancer agents & Biologic therapy
23 Dec 2019 FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-positive Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
20 Dec 2019 EMA Recommends Extension of Therapeutic Indications for Ramucirumab Lung and other thoracic tumours - Anticancer agents & Biologic therapy
19 Dec 2019 EMA Recommends a Change to the Terms of the Marketing Authorisation for Akynzeo Palliative and supportive care